Kornimate/medical-research-clean huggingface dataset:
1-month vs 12-month dapt for acs patients who underwent pci stratified by ivus: ivus-acs and ultimate-dapt trials

Conditions: Coronary Artery Disease

Summary: prospective, multicenter, randomized, double-blind, placebo-controlled trials.

a total of 3486 subjects with acs who met inclusion criteria and do not have any exclusion criterion will be randomized to ivus- or angiography-guidance group (first randomization). in the ivus-guidance group, ivus will be used to evaluate the lesion's specificity and to measure lesion length, landing zone, and reference vessel diameter prior-to stenting; and to assess stent expansion, extension, apposition, and possible complications after stent implantation. the ivus- defined criteria for the optimal stent deployment included: 1) the minimal stent area (msa) in the stented segment is \>5.0 mm\^2, or 90% of the mla at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is \ type b edge dissection. further treatment will be required if stenting procedure is defined as suboptimal according to ivus definition. ivus will be not allowed to be used in the angiography-guidance group. those patients who have had no death, stemi, stroke, st, tvr or major bleeding (barc 3 or 5) within 30 days and have continued on aspirin and ticagrelor for 30 days without interruption for \>48 hours will be randomized 1:1 to: 1. ticagrelor plus+ matching placebo for an additional 11 months (sapt group) 2. ticagrelor plus aspirin (study drug) for an additional 11 months (dapt group) follow-up of all subjects will continue for 1 year with an option for additional follow-up to 3 years.

Eligibility criteria:
inclusion criteria: enrollment into the study will require meeting at least one of these clinical syndromes within 1 month. * unstable angina, defined as rest pain for 5-30 minutes or deteriorative exertional angina with either a) transient st segment depression or elevation, or b) angiography showing a visually estimated diameter stenosis ≥90% or a ruptured plaque or thrombotic lesion * non-st elevation myocardial infarction (nstemi), defined as positive troponin consistent with clinical syndrome. * st elevation mi (stemi) exclusion criteria: * unable or unwilling to provide informed consent * stroke within 3 months or any permanent neurologic deficit, and prior intracranial bleed, or any intracranial disease such as aneurysm or fistula * previous coronary artery bypass graft (cabg) * any planned surgery within 90 days * any reason why any antiplatelet therapy might need to be discontinued within 12 months * severe chronic kidney disease defined as an estimated glomerular filtration rate (egfr) \< 20 ml/min/1.73m\^2 * need for chronic oral anticoagulation (warfarin/coumadin or direct oral anticoagulants) * platelet count \< 100,000 mm\^3 * contraindication to aspirin * contraindication to ticagrelor * liver cirrhosis * women of child-bearing potential * life expectancy \< 1 year * any condition likely to interfere with study processes including medication compliance or follow-up visits (e.g. dementia, alcohol abuse, severe frailty, long distance to travel for follow-up visits, etc.)
molecular response to custom manual physiotherapy treatment of fibromyalgia & chronic fatigue syndrome (cfs)

Conditions: Fibromyalgia (FM); Chronic Fatigue Syndrome (CFS)

Summary: fibromyalgia (fm)and chronic fatigue syndrome (cfs) are complex diseases often presenting overlapping symptomatology. manual therapy (mt) protocols report benefits for pain treatment of fm, but the underlying mechanisms for patient improvement remain unknown. the main goal of this study is to assess the molecular changes associating to mechanical and additional mt triggers, possibly involved in patient symptom improvement.

patients with fibromyalgia as primary diagnosis assessed by the 1990 \& 2010 acr (american college of rheumatology) criteria, presenting or not comorbid cfs, according to the canadian and international cfs criteria, age 40-75 and bmi\<35 (n=40), will be subjected to physiotherapy treatment consisting on 8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 n by a single operator (collegiate physiotherapist). blood samples (10-20mls/participant) will be obtained before and after first treatment, and after fourth and last treatment to determine molecular blood changes associated to the physiotherapy protocol applied. pbmc (peripheral blood molecular cells) transcriptome before and after treatments (rnaseq) will be studied towards identifying treatment-associated differential expression, mechanomir profiles included. patient health status with treatment will be monitored by fiq, mfi and sf-36 questionnaires, in addition to an anonymized satisfaction questionnaire to register potential undesired secondary effects.

Eligibility criteria:
inclusion criteria: * diagnosis of fm with or without comorbid cfs * not receiving hormone therapy * not suffering from other diseases * without previous history of cancer * not actively participating in any pharmacological trial * not taking medication for at least 12 hours before blood draw * having signed informed consent exclusion criteria: - any uncompliance with what is described as inclusion criteria

Keywords: manual therapy physiotherapy fibromyalgia (fm) chronic fatigue syndrome (cfs) rnaseq microrna mechanomir
ultrasound evaluation of the rotator cable and associated structures.

Conditions: Shoulder Pain

Summary: this study will use healthy volunteers and patients with shoulder problems (pain or impaired movement). ultrasound will be used to image and document the appearance of both normal and abnormal shoulder structures.

the purpose of this study is to document normal and abnormal appearances of various shoulder structures (rotator cable and rotator cuff). this study will recruit healthy volunteers and patients who have been referred to radiology for a symptomatic shoulder (a shoulder that is causing the patient pain, or is limited in its ability to move.) both groups will undergo ultrasound imaging of the shoulder.

Eligibility criteria:
inclusion criteria: * patients with shoulder pain referred to radiology for ultrasound of shoulder exclusion criteria: * patients less than 18 years of age

Keywords: ultrasound rotator cuff
clinical study to assess the long-term safety, tolerability, and efficacy of macitentan in subjects with eisenmenger syndrome

Conditions: Pulmonary Arterial Hypertension

Summary: long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of eisenmenger syndrome.


Eligibility criteria:
inclusion criteria: subjects with es (including those with down syndrome) having completed the double-blind ac-055-305 / maestro study as scheduled, i.e., who remained in the double-blind study up to week 16 (whether or not they were still taking study drug at the end of this period). exclusion criteria: subjects who prematurely discontinue double-blind study drug during the ac-055-305 / maestro study due to: * an ae assessed as related to the use of study drug, * or elevated liver tests (related or unrelated to study drug).

Keywords: eisenmenger syndrome exercise capacity
comparison of the efficacy of inflexal v with a commercially available influenza vaccine in young children

Conditions: Influenza

Summary: a study to assess whether the northern hemisphere 2009/2010 season influenza vaccine inflexal v is as immunogenic as a locally sourced competitor vaccine in young children.


Eligibility criteria:
inclusion criteria: * ≥6months to ≤35 months-old healthy children (male or female) born at term after normal pregnancy * recording of medical history and physical examination reveal no abnormality * the parent/legal guardian of the participating child must sign the written informed consent and agree to provide a blood sample taken from the child pre- and post-immunization exclusion criteria: * hypersensitivity to eggs, chicken proteins, polymyxin b, neomycin or any component of the vaccine * previous vaccination against influenza * at time of enrollment, presentation of clinical symptoms of active infection and/or body temperature ≥38°c * confirmation or suspicion of immunosuppressed status (including cancer), or confirmation of immunodeficiency disease (congenital or acquired including hiv) * medical treatment (\>2 weeks) with immune suppressant or immune modulating drugs including systemic steroids during the last 3 months before immunization or at present, as follows: long-term oral prednisone or other equivalent steroid: ≥0.5mg/kg/day (note: administration of local or inhaled steroids before or during the study is allowed) * treatment with immunoglobulins or blood products during the last 3 months before immunization or such treatment scheduled during the study * participation in other clinical trials during the last 3 months before immunization or intention to participate during this study period * at present or during the last 6 months before immunization: radiotherapy or treatment with cytotoxic drugs * other vaccination with a killed vaccine within 14 days before immunization or with an attenuated vaccine within 28 days before immunization (note: after subject inclusion vaccines of the immunization program for children are allowed upon the physician's discretion. however, immunization on the same day must be avoided) * family history of guillain-barré syndrome * severe congenital deficiency or disease * antecedent of neurological disease or epileptic attack * severe cardiopulmonary disease with possibility to influence the study result * disturbance of coagulation or under anticoagulant treatment, likely to be contraindicated to i.m. injection * suspected non-compliance

Keywords: influenza virus vaccination immunisation
a study to evaluate rucaparib in participants with solid tumors and with deleterious mutations in hrr genes

Conditions: Solid Tumor

Summary: a phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in homologous recombination repair (hrr) genes.


Eligibility criteria:
key inclusion criteria: * unresectable, locally advanced or metastatic solid tumor and relapsed/progressive disease * measurable disease per recist v1.1 or modified recist v1.1 and pcwg3 (for prostate cancer) * have a deleterious mutation (germline or somatic) in brca1, brca2, palb2, rad51c, rad51d, bard1, brip1, fanca, nbn, rad51 or rad51b. note: breast cancer patients that are her2 negative and have germline brca1 or brca2 mutations and patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or metastatic castration-resistant prostate cancer with brca1 or brca2 mutations are ineligible for this trial. * at least one prior line of therapy extending overall survival or standard of care therapy for advanced disease. note: some tumor types have specific inclusion/exclusion criteria for previous treatments. * ecog 0 or 1 * tumor tissue available for genomic analysis, or must be willing to have a biopsy if no archival tumor tissue available * adequate organ function * life expectancy of 4 months key exclusion criteria: * active central nervous system brain metastases, leptomeningeal disease or primary tumor of cns origin * active second malignancy (exceptions: successfully treated malignancy with no active disease for 1 year, surgically cured and/or low-risk tumors, or patients receiving ongoing anticancer hormonal therapy for a previously treated cancer) * pre-existing gastrointestinal disorders/conditions interfering with ingestion/absorption of rucaparib * prior treatment with a parp inhibitor * more than 3 prior lines of chemotherapy in the locally advanced/metastatic setting * history of myelodysplastic syndrome or acute myeloid leukemia

Keywords: rucaparib parpi rare tumor solid tumor co-338 ovarian cancer prostate cancer pancreatic cancer breast cancer lung cancer colon cancer gastric cancer bladder cancer colorectal cancer parp inhibitor homologous recombination dna repair lodestar germline somatic brca1 brca2 palb2 rad51c rad51d bard1 brip1 fanca rad51 rad51b sarcoma hrr hrd platinum sensitive platinum resistant primary peritoneal cancer fallopian tube cancer tumor agnostic basket study basket trial metastatic locally advanced esophageal cancer leiomyosarcoma ampullary carcinoma carcinosarcoma endometrial cancer cervical cancer
implementing virtual parent support groups for eating disorders across canada

Conditions: Eating Disorders

Summary: during the covid-19 pandemic, canada has experienced a surge in new pediatric eating disorder cases and hospitalizations and long treatment waitlists, with parents experiencing anxiety due to a lack of support. as it has not been rigorously studied, there is an urgent need to understand and mitigate the impact of the covid-19 pandemic on children, youth, and families living with eating disorders across canada. the investigator's proposed research has two goals. first, the investigators plan to understand the impact of the covid-19 pandemic faced by this population throughout the country, as well as describe stakeholder views on virtual parent-led peer support groups. given the increased burden faced by parents of children with eating disorders during the covid-19 pandemic, the second goal is to study whether the national implementation of virtual parent-led peer support groups helps to mitigate the impact of the pandemic among affected parents. the investigators will use qualitative semi-structured interviews to gather an understanding of the impact of the pandemic on relevant stakeholders across the country. at the same time, the investigators will evaluate the feasibility and acceptability of the implementation of virtual parent-led peer support groups in several regions of canada by examining parent and parent peer support provider experiences.


Eligibility criteria:
inclusion criteria: * have the capacity to write, speak and understand english * have access to a computer and internet * among parents enrolled in the virtual parent-led peer support groups, they must have a child or adolescent (\<18 years of age) diagnosed with an eating disorder * among youth and parents of youth with an eating disorder in the qualitative interviews component of the study, they/their child must either be on a waiting list for eating disorder treatment, actively in treatment, or post-treatment; the youth must be \<18 years of age and the parent must have a child \<18 years of age * among clinician/administrators in the qualitative interviews component of the study, they must work within pediatric eating disorder programs or lifespan eating disorder programs. exclusion criteria: * no lived or professional experience in the field of eating disorders * don't have the capacity to write, speak and understand english * don't have access to the internet/computer

Keywords: eating disorder parent support group covid-19
training program and mobile health message on promoting family holistic health

Conditions: Physical Activity; Health Behavior; Quality of Life

Summary: in this study, the investigators would use the training workshops as a capacity build method to deliver the holistic health knowledge for the trainers and ambassadors implementing and assisting the community-based programs for the public. the investigators hypothesize that the training workshops and mobile health messages would promote the health awareness and the health of the participants. the investigators would expect the participants influence the health behavior and attitude of their family members.

holistic health is an integration and interaction of physical and psychosocial health. positive psychology is a science of happiness, which focuses on positive emotions and personal strengths. it is used as a preventive and complementary medicine, which also is crucial component in family holistic health (happiness, harmony and health). healthy diet can help to achieve energy balance and healthy weights. sufficient daily consumption of fruit and vegetables, as well as limitation on the intake of sugar, salt and fat could prevent major diseases, such as cardiovascular diseases and certain cancers. physical activity is believed to contribute to physical and mental health, as well as social well-being. however, physical inactivity was found to be a local and worldwide issue. and most hong kong people are having sedentary lifestyle. studies show that the increase of physical activity and healthy diet reduce the risk of chronic diseases, and improve cardio-pulmonary functions; whereas sedentary behaviors increase the risk. the project team will schedule the training workshops for the trainers and ambassadors implementing and assisting community-based programs for the public. the investigators hypothesize that the training workshops and mobile health messages would promote the health awareness and the health of the participants. the investigators hypothesize that the training workshops promote the participants' knowledge and enhance the participants' behaviors related to family holistic health, such as positive psychology, physical activity and healthy diet. the investigators would expect the participants influence the health attitude of their family members.

Eligibility criteria:
inclusion criteria: * chinese speaking * able to complete study questionnaire exclusion criteria: * not fit the inclusion criteria

Keywords: physical activity family well-being
pilot study to evaluate the interest of pdl in the management of telangiectasia of the face and neckline in systemic scleroderma

Conditions: Telangiectasia

Summary: this single-center, prospective, open-label, quasi-experimental, intra-individual comparative study will include a consecutive cohort of 21 patients with diffuse or limited, minimally active scleroderma with 3 to 30 years of evolution. patients will have 4 sessions of pulsed dye laser 595 nm spaced 8 weeks apart. the final quadruple evaluation by several evaluators will be 2 months after the last session, on the following criteria: evolution of the number of telangiectasia; subjective improvement score (linkert scale); impact on quality of life (skindex score); visual analog pain scale (vas); adverse events (aes), including discontinuation of treatment due to post-session purpura (at-pps); patient satisfaction (yes or no).

primary objective: to evaluate the efficacy of pulsed dye laser treatment on facial and neckline telangiectasias in systemic scleroderma by comparing the mean number of telangiectasias. secondary objectives: evaluation of the aesthetic efficacy by the patient, observer and adjudication committee evaluation of the impact on the quality of life after treatment (skindex) evaluation of treatment tolerance in terms of pain (vas) and adverse events (purpura, oozing, hyperpigmentation, hospitalization)

Eligibility criteria:
inclusion criteria: * patient followed in dermatology and/or internal medicine at the university hospital of caen for systemic scleroderma * patient with telangiectasias related to scleroderma * patient with an aesthetic prejudice exclusion criteria: * patient with previous laser treatment for facial telangiectasias. * tanned, irritated or traumatized facial skin * patient not affiliated to the social security system * pregnancy
mrsa colonization and control in the dallas county jail

Conditions: Methicillin-resistant Staphylococcus Aureus; Skin Diseases, Infectious; Soft Tissue Infections

Summary: the goal of this 3-year project is to control the spread of community-associated methicillin-resistant staphylococcus aureus (ca-mrsa) in the dallas county jail. ca-mrsa is a bacterium spreading rapidly through healthy populations and becoming an epidemic in many regions of the u.s. many people in the community are asymptomatically colonized by mrsa. there have been outbreaks of mrsa infections at prisons and jails. we will study the spread of mrsa in the jail to better understand how the bacteria are transmitted from person to person there and how we can prevent their transmission. all detainees asked to participate must give informed consent to do so; their privacy will be carefully protected. detainees with a history of allergy to chg will be excluded. seventeen objects in the jail will be sampled for contamination with mrsa. bacteria will be collected from all cultures obtained from patients with bacterial skin infections for 18 months in a part of the jail in order to determine how frequently these infections are caused by mrsa relative to other bacteria. a group of about 1500 adult detainees will be tested for colonization with mrsa in order to determine how commonly detainees carry the bacterium. a cluster-randomized 6-month study will be undertaken among these detainees and those who take their places when they leave the jail to determine if chlorhexidine (chg)-containing disposable wash cloths for skin cleaning can decrease the prevalence of mrsa skin or nose colonization. detainees receiving chg cloths (about 500 detainees) will be compared to detainees receiving water-soaked cloths for skin cleaning (about 500 detainees) or no intervention (about 500 detainees). the primary outcome will be a difference in average colonization prevalence in detention tanks, which are discrete detention units housing detainees, comparing the usual care to the chg-exposed tanks after 6 months of chg cloth use. a secondary outcome will be a decrease in skin infections from any cause in the tanks receiving chg compared with usual care. all of the mrsa isolates and a sample of the s. aureus isolates susceptible to methicillin from specimens colonizing or infecting detainees, as well as those contaminating surfaces and objects in the jail will be tested genetically in order to determine which strains of mrsa are present in the jail. this study may identify ways to stop the spread of mrsa among people in jails and prisons, as well as other places.


Eligibility criteria:
inclusion criteria: * admission to a participating tank in the jail exclusion criteria: * history of hypersensitivity reaction to chlorhexidine

Keywords: mrsa methicillin-resistant staphylococcus aureus chlorhexidine asymptomatic colonization asymptomatic colonization, mrsa skin and soft tissue infections